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re-intervention at 5 years (7% vs. 15%); complexity of follow-up (with vs. without 
CT examination); risk of major complications (2% vs. 5%); additional cost of inter-
vention (c0 vs. c2000). Patients preferences were elicited before treatment (NAIF) and 
after treatment with open surgery (OPEN) or endovascular procedure (EVAR). a 
segmentation conditional logistic regression model was applied to estimate relative 
importance (RI) assigned to each characteristic according to patients’ experience with 
treatment. RESULTS: A total of 160 patients participated (aged 49–88 years, 91.7% 
male) from 9 hospitals. Fifty-two percent were NAIF at enrolment. Overall, half 
patients were treated with OPEN, half with EVAR. One most important characteristic, 
risk of procedural major complications, was considered more important by NAIF and 
EVAR than OPEN (RI = 31.7% and 22.0% vs. 11.0%). Additional costs were more 
important to OPEN (RI = 38.3%) than NAIF (25.2%) and EVAR (19.5%). Local 
anaesthesia was more important to EVAR (24.8%) than NAIF or OPEN (RI = 8.5%). 
Risk of repeating the procedure was similarly important to treated patients (RI = 
17.5%), less to NAIF (RI = 12.3%). Recovery time was more important to OPEN (RI 
= 14.3%) and EVAR (RI = 10.3%) than NAIF (8.6%). Type of follow-up tests was 
least important, with OPEN and NAIF preferring less complex tests (RI = 4–10%), 
but EVAR preferring more complex tests (RI = 6%). CONCLUSIONS: Preferences 
depend on experience, knowledge and expectancies. Understanding patients’ prefer-
ences can help physicians to optimize beneﬁ ts of treatments.
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OBJECTIVES: Individuals with type 2 diabetes mellitus (T2DM) are known to have 
poorer quality of life and more depressive symptoms than those without diabetes, yet 
the impact may be in part due to comorbid conditions. This study compared quality of 
life and depression among adults with T2DM and comorbid hypertension (HTN) and 
obesity with adults reporting T2DM only. METHODS: Respondents to the Study to 
Help Improve Early evaluation and management of risk factors Leading to Diabetes 
(SHIELD), a large US survey, self-reported their height, weight, and comorbid condi-
tions, and completed the Short Form- 12 (SF-12) and Patient Health Questionnaire 
(PHQ-9, depression assessment). Respondents reporting T2DM and HTN and obesity 
(body mass index [BMI] ≥30 kg/m2) were identiﬁ ed and compared with a T2DM-only 
group. RESULTS: Respondents with T2DM and comorbid HTN and obesity (n = 1292) 
were similar to T2DM-only respondents (n = 349) in race, education, smoking, and 
cardiovascular disease history (all p > 0.05), but were younger and were more likely to 
be men and have lower income (P < 0.01). Respondents with T2DM, HTN and obesity 
had signiﬁ cantly lower Physical and Mental Component Summary scores (37.3 and 
50.9, respectively) than T2DM-only respondents (45.8 and 53.5, respectively, P < 
0.0001). Mean PHQ-9 scores were signiﬁ cantly higher among T2DM respondents with 
comorbid HTN and obesity (5.0 vs. 2.5, P < 0.0001), indicating greater depression 
burden. Approximately 16.5% of respondents with T2DM, HTN and obesity had 
moderate to severe depression (PHQ-9 scores ≥15), compared with 6.1% of respondents 
with T2DM only (P < 0.0001). CONCLUSIONS: SHIELD respondents with T2DM, 
HTN and obesity report a lower quality of both physical and mental health and more 
depression symptoms than the T2DM-only group. More research is needed to determine 
whether the poor quality of life and greater depression in this population affects self-
management of their diabetes and comorbid conditions.
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OBJECTIVES: This study aimed to investigate the health-related quality of life 
(HRQoL) of coronary heart disease (CHD) patients and healthy subjects in Hong 
Kong. METHODS: This study was a one-year prospective cohort with two groups of 
study populations, the patient group and healthy subject group. Thirty-three eligible 
patients were recruited from Prince of Wales of Hospital. The HRQoL data using 
Short-Form 36-item Health Survey (SF-36) were collected just after percutaneous 
coronary intervention (PCI) (baseline) and one year post-PCI. Thirty-ﬁ ve healthy 
subjects who were recruited from two elderly centres and parents of School of Phar-
macy (SOP) students, were also interviewed by SF-36. This study consists of two parts. 
In the ﬁ rst part, the HRQoL data of healthy subjects were compared with patients at 
baseline and 1 year post-PCI respectively. In the second part, the improvement in 
HRQoL of PCI patients at baseline and 1 year post-PCI was compared. RESULTS: 
In the ﬁ rst part of study, healthy subjects had signiﬁ cantly (P < 0.05) higher scores in 
role-physical (79.3 ± 36.6 vs. 53.8 ± 48.1), vitality (65.1 ± 23.8 vs. 49.5 ± 33.7) and 
role-emotional (93.3 ± 15.8 vs. 72.7 ± 39.5) than the patients at baseline. Patients’ 
HRQoL returned to similar level with healthy subjects after 1 year of PCI treatment. 
In the second part of the study, patients had signiﬁ cant (P < 0.05) improvements in 
bodily pain (12.7 ± 30.3) and vitality (16.1 ± 33.1) after 1 year. CONCLUSIONS: 
This study showed that the HRQoL of CHD patients was poorer than healthy popula-
tion in Hong Kong, but returned to similar level as healthy population after 1 year of 
PCI treatment. In addition, signiﬁ cant HRQoL improvements had been seen in patients 
after 1 year of PCI, especially in bodily pain and vitality.
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OBJECTIVES: To evaluate the impact of chronic venous disease (CVD) on patients’ 
professional activity and its consequence on patients’ quality of life (QOL) in 
Romania. METHODS: A large observational, multicentre, descriptive survey in CVD 
was implemented in Romania in 2009. Impact of CVD on patients’ professional 
activities and QOL were documented based on a patient self-administered question-
naire. The CIVIQ-14 was used to assess QOL (score 0 for very good to 100 for bad 
QOL). Patient data were crossed with their general practitioner evaluations on the 
severity of the disease. RESULTS: Out of 2542 screened patients, 2294 ﬁ lled in the 
questionnaire (90.2%). Among CVD patients, 7% had had hospitalization because of 
the disease, while 7% had changed their professional activities or had lost working 
days. Number of lost working days over the previous 5 years exceeded 1 week for 
most (40% lost >1 week, 35% >1 month, 16% <1 week). Patients who lost less than 
1 working week, between 1 week and 1 month and more than 1 month due to CVD 
had a worsened QOL (respectively 28.71 ± 24.32, 31.4 ± 17.73 and 31.8 ± 16.69 
CIVIQ-14 score) QOL scores paralleled the severity of CVD, going from 15.64 ± 
14.94 in C0s patients (symptoms only, according to the CEAP) to 51.79 ± 30.43 in 
C6 (patients with ulcer). The presence of pain decreased QOL (30.49 ± 19.04). QOL 
scores associated to work absenteeism varied from 21.98 ± 15.05 to 49.49 ± 20.06 
depending on absenteeism frequency (from 1 to 3 times respectively) CONCLUSIONS: 
CVD generates an important negative professional impact in Romania with productiv-
ity losses. Quality of life impairment occurs from the ﬁ rst symptoms of CVD and it 
is correlated to the work absenteeism duration and frequency. Three times out of work 
is associated to a QOL score comparable to the one quoted between grades 4 and 5 
of the CEAP classiﬁ cation.
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OBJECTIVES: This study compared ﬁ ve methods of summarizing symptom data and 
the association of these measures with the outcome health related quality of life 
(HRQL) in patients who had experienced an acute coronary syndrome event (ACS). 
METHODS: All patients listed in an ACS registry (treated for ACS and discharged 
from a university afﬁ liated hospital) during a 3 year period were mailed a question-
naire that assessed symptom status, demographics, cardiac functional status and 
therapy, comorbidity, ACS type and HRQL (SF-8 and EQ-5D). The symptom survey 
included 24 symptoms and measured the occurrence, frequency, and distress associ-
ated with each symptom during the previous four weeks. Symptom summary measures 
included summed, averaged, and multiplicative (Symptom Product) values of each 
symptom characteristic. Bivariate correlations and multivariate regression analysis 
were used to assess the association of each symptom summary measure with HRQL, 
controlling for other patient, disease, and treatment characteristics. RESULTS: A total 
of 490 of 1217 patients (40%) responded. The mean age was 65.7 ± 11.3 years; 67.7% 
male;94.0% Caucasian;PCS-8 53.7 ± 10.5; MCS-8 49.5 ± 9.5; and EQ-5D VAS 73.6 
± 20.5. The Symptom Sum = 7.8 ± 4.9, Symptom Frequency Average = 2.5 ± 0.72, 
Symptom Distress Average = 2.2 ± 0.8, Symptom Distress Sum = 18.6 ± 14.8, and 
Symptom Product = 51.7 ± 48.3. Bivariate correlations demonstrated that the 
Symptom Sum and Symptom Product had the highest correlation (>0.54) with the 
HRQL domains, while Symptom Frequency Average was the lowest (0.24–0.33). 
The same pattern was seen with the multivariate regression model. The model adjusted 
R-square for the Symptom Sum and Symptom Product measures were higher than the 
other measures, with the Symptom Product having the highest correlation. The 
R-square values ranged for these two measures depending on the HRQL domain; PCS 
(0.38–0.44), MCS (0.33–0.35), EQ-5D (0.34–0.39). CONCLUSIONS: Researchers 
may consider using Symptom Sum or a Symptom Product measures when attempting 
to summarize the association of symptoms with HRQL in ischemic heart disease 
patients.
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OBJECTIVES: To analyze, for the ﬁ rst time in a large Spanish population of heart 
failure patients, quality of life according to NYHA class II, III or IV using generic 
and speciﬁ c quality of life questionnaires. METHODS: A descriptive analysis of a 
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multicenter, prospective observational study was performed. Patients who met inclu-
sion criteria were followed-up for a period of 12 months, with 3 visits programmed 
at baseline, 6 months and 12 months. a total of 9 Spanish hospitals were involved in 
the study. Questionnaires used to measure quality of life were: EQ-5D (generic ques-
tionnaire), Minessotta living with heart failure- MLWHF (speciﬁ c questionnaire) and 
Barthel Index (index of independence). RESULTS: A total of 450 patients were 
included, 76% men, mean age was 62.6 years. 66.1% were in NYHA class II, 32.7% 
NYHA class III and 1.1% NYHA class IV. Prevalence of ischemic cardiopathy was 
33.5%. 35% of patients had an implantable device (ICD, RCT or pacemaker). Sig-
niﬁ cant differences were observed in Barthel Index’s scores depending on class: class 
I 97.6 ± 6.7 vs. Class III-IV 91.8 ± 14.6. Related to EQ-5D tariffs, individuals in class 
II had a mean value of 0.8407 ± 0.1887 (out of 1), and mean VAS value of 60.6 ± 
17.39 (out of 100). Individuals in NYHA class III or IV had a mean score of 0.6624 
± 0.2848, and mean VAS value of 51.93 ± 17.15 (out of 100). In a MLWHF question-
naire analyses, patients in NYHA class II showed a mean score of 32.52 ± 20.69 while 
patient in NYHA class III-IV showed a mean score of 50.44 ± 18.23. CONCLU-
SIONS: Our ﬁ ndings showed the results from the three questionnaires were generally 
consistent with each other and values reported from other countries in the 
literature.
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OBJECTIVES: To characterize health-related quality of life (HRQoL) in patients with 
pulmonary arterial hypertension (PAH) in relation to persons of similar age and gender 
in the general United States (US) population. METHODS: Data were obtained from 
a large phase III clinical trial in which patients (n = 274) were randomized to sildenaﬁ l 
or placebo for 12 weeks. We characterized HRQoL using responses to the Short 
Form-36 General Health Survey (SF-36) obtained at baseline; the SF-36 addresses eight 
HRQoL domains: physical functioning (PF), role functioning–physical (RP), bodily 
pain (BP), general health (GH), vitality (VT), social functioning (SF), role function-
ing–emotional (RE), and mental health (MH). Values for these eight domains were 
then standardized to US population norms for persons aged 45–54 years (mean age 
of patients in trial was 49 years). RESULTS: A total of 39% and 58% of patients 
were designated at baseline as Functional Class (FC) II and III, respectively (<1% and 
3% were designated as FC I and IV), with 75% women. Standardized mean scores 
were 30.4 for PF, 27.9 for RP, 47.8 for BP, 34.2 for GH, 41.2 for VT, 38.9 for SF, 
34.9 for RE, and 43.7 for MH. In comparison with the US population, whose mean 
score for each domain = 50, PF, RP, GH, SF, and RE were all substantially worse for 
PAH patients. Additionally MH and VT were marginally worse among PAH patients, 
and BP was comparable to US norms. CONCLUSIONS: With the exception of bodily 
pain and mental health, PAH patients have substantially poorer SF-36 scores than 
their peers in the US general population, especially in terms of physical functioning, 
role functioning-physical, role functioning-emotional, and general health.
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OBJECTIVES: The aim of the present study was to evaluate the effect of 700 mg and 
1400 mg pomegranate seed capsules on body weight and blood pressure for a period 
of 60 days at time interval 7, 14, 21, 28, 45 and 60 days respectively. METHODS: 
At the beginning of the study twenty four healthy human volunteers were selected. 
On the basis of BMI two broader groups, i.e. group 1 taking 700 mg pomegranate 
capsules and group 2 taking 1400 mg pomegranate capsules were designated and both 
the groups were subdivided on the basis of diet control and exercise i.e. group1 (IA, 
IB) and group 2(IIA, IIB). Group IA and IIA took pomegranate capsules without diet 
and exercise while IB and IIB took the capsules with diet and exercise. Hypertensive 
patients from these groups were included in both groups who were categorized and 
evaluated separately and compared with normal individuals. RESULTS: The result of 
investigation indicated that both doses of pomegranate seeds capsules had signiﬁ cantly 
reduced the body weight and blood pressure proﬁ le (both systolic and diastolic) in all 
groups when compared with their baseline values. However both doses caused equal 
reduction of body weight and blood pressure as no signiﬁ cant difference was present 
in both doses (p-value > 0.05). CONCLUSIONS: Thus on the basis of results obtained 
after conducting our study it was concluded that pomegranate seed capsules have 
established their efﬁ cacy and safety proﬁ le for obesity control and hypertension 
management.
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OBJECTIVES: To measure how VKA’s patients assess their treatment in terms of 
medication intake constraints, monitoring and psychological impact related to per-
ceived risk. METHODS: Questionnaires to patients under VKAs for at least 3 months. 
Questionnaires were distributed through 150 retail pharmacies spread over all France 
from November 2009 to March 2010. a random distribution of questionnaire was 
made. RESULTS: 1094 questionnaires were administered. Study included 58% men 
and 42% women aged >65 years for 72%; patients aged more than 75 years repre-
sented 43%. Patients were treated in majority by ﬂ uindione (82.3%) and for more 
than 3 years (65.1%). Patients were treated in majority for cardiac rhythm disorder 
(40%). More than ¾ (77%) of VKAs patients consider their treatment being a burden 
even though being vital. Treatment is judged as being a constraint because of the 
obligation to adapt dosages according to coagulation monitoring (42%), and due to 
the necessity to contact their physician after each blood sample (25%). The require-
ment to permanently have a monitoring is considered as constantly reminding the 
associated risk (65%), expectation of coagulation monitoring results generate anxiety 
for more than ¼ of patients (27%). Majority of patients acknowledge that regular 
blood sampling is a constraint (53%) and that the treatment would be more conve-
nient without these constant blood samplings (60%). In parallel, 38% of patients 
interviewed consider that the VKA treatment constraint is reinforced by the fact that 
they cannot eat what they would like. Patient preference for a new treatment is in 
priority: a treatment without regular blood sampling (62%); a treatment for which 
the daily anticoagulant dosage does not need adaptation (60%). CONCLUSIONS: 
Treatment by VKAs is perceived as burdensome and risky by a majority of patients 
due to the constant monitoring required and the uncertainty of the good blood dosage. 
CARDIOVASCULAR DISORDERS – Health Care Use & Policy Studies
PCV120
COMBINED MEDICATION CHOICE AND PATIENT PERSISTENCE IN 
HYPERTENSION THERAPY: EVIDENCE OF REAL-LIFE EFFECTIVENESS
Molnár MP1, Dankó D1, Katona L2
1Corvinus University of Budapest, Budapest, Hungary; 2Hungarian National Health Insurance 
Fund Administration, Budapest, Hungary
OBJECTIVES: While hypertension treatment guidelines emphasize the medical ben-
eﬁ ts of combined medication choice, consumption patterns of antihypertensive drugs 
raise worldwide several questions related to real-life therapeutic and cost-effectiveness. 
Hungary has a relatively poor track record: international comparative studies show 
Hungarian patients’ adherence to treatment to fall behind not only desirable targets 
but also international average values. In our analysis, we start from the hypothesis 
that medical beneﬁ ts achievable through combined therapy are weakened through 
inadequate patient adherence, and we investigate into the health loss caused to Hun-
garian patients by insufﬁ cient persistence in combined hypertension therapy. Our goal 
is to determine how the real-life consumption patterns of combination hypertension 
therapy impact real-life therapeutic effectiveness and cost-effectiveness. METHODS: 
We use itemized prescription-level data from the Hungarian National Health Insur-
ance Fund Administration’s (NHIFA) database. Our research covers patients whose 
therapy was initiated during 2008 or 2009 with high-value ﬁ x-dosage (one-pill) and 
non-ﬁ x-dosage (multiple-pill) angiotensin-converting enzyme inhibitor (ACEI) and 
calcium channel blocker (CCB) combinations, or angiotensin-receptor blocker (ARB) 
and CCB combinations. RESULTS: Adherence to treatment is measured as persistence 
on the initiating combination therapy. Firstly, ‘hard’ persistence (which does not allow 
for add-on therapies) and ‘add-on’ persistence (which allows for additional active 
substances being added to the therapy regime) are separately calculated, both for ﬁ x-
dosage and non-ﬁ x-dosage combinations. Secondly, if the initiating therapy is a ﬁ x-
dosage combination, parallel consumption of monocomponents is also analyzed. 
Thirdly, we carry out a switch analysis to determine the active substances that patients 
had been taking before receiving a ﬁ x-dosage combination, or take after abandoning 
the ﬁ x dosage combined therapy. CONCLUSIONS: We hypothesize that substantial 
societal loss is caused by patient non-adherence in hypertension treatment and clinical 
advantages of combination therapies are signiﬁ cantly impaired. Our research will 
deliver exact calculations for the extent of the societal loss.
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OBJECTIVES: Cardiovascular risk factors remain poorly controlled across Europe 
despite clinical guidelines. The European Study on Cardiovascular Risk Prevention 
and Management in Daily Practice (EURIKA) investigated the use of cardiovascular 
risk assessments tools and guidelines, and explored factors limiting their use. 
METHODS: Physicians (n = 806) from 12 European countries answered questions 
regarding their work setting, their assessment of patients with cardiovascular risk 
factors, and their use of risk calculation tools and clinical guidelines. RESULTS: 
Participating physicians worked in primary care centres or outpatient clinics; 63.8% 
were GPs. The majority (69.3%) reported using global risk calculation tools. Written 
charts were the preferred method (69.9%), followed by software (33.0%). The most 
popular tools were SCORE (European Society of Cardiology [ESC]; 52.4%), 
